Core Insights - Vaso Corporation's shares have increased by 27.3% since the earnings report for Q3 2025, significantly outperforming the S&P 500 Index, which declined by 2.2% during the same period [1] Financial Performance - In Q3 2025, Vaso reported total revenue of $22.7 million, a 9.1% increase from $20.8 million in the same quarter last year [2] - The company achieved a net income of $1.7 million, a turnaround from a net loss of $1.2 million a year earlier, attributed to higher revenue, improved gross margins, and reduced operating expenses [2][4] - Gross profit rose by 18.2% to $13.9 million from $11.8 million in Q3 2024, reflecting enhanced margins across business segments [4] Segment Performance - Professional sales service revenue increased by 18.7%, IT segment revenue grew by 1.2%, and equipment segment revenue rose by 8%, primarily driven by higher ARCS software subscription revenue in the U.S. [3] - Subscription revenues continue to be a significant portion of total revenues, supporting recurring cash generation [5] Cash Flow and Financial Health - Vaso reported operating cash flow of $2.8 million for the quarter and $9 million for the first nine months of 2025, a substantial increase from $3.6 million in the same period of 2024 [6] - Cash and cash equivalents stood at $34.9 million as of September 30, 2025 [6] Management Insights - Management noted that all three business segments contributed to revenue growth, with the professional sales services division benefiting from increased equipment deliveries from GE HealthCare [7] - CEO Dr. Jun Ma emphasized the strong balance sheet, rising deferred revenue, and sustained momentum in subscription-based income streams [8] Profitability Drivers - The return to profitability was driven by revenue growth, better product mix, and improved margin performance, particularly in the equipment segment [9] - Operating expenses grew at a slower pace than gross profit, improving operating income to $1.5 million from a loss of $1.4 million last year [10] Future Outlook - Vaso did not provide formal financial guidance but indicated expectations for stable topline performance supported by recurring subscription revenues and increasing deferred revenue [11] - No significant acquisitions, divestitures, or restructuring initiatives were disclosed during the quarter [12]

PLAINVIEW, N.Y., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales services and proprietary medical products, today announced operating results for the three months ended September 30, 2025. “For the third quarter of 2025, the Company’s total revenue was $22.7 million, an increase of $1.9 million, or 9.1%, from prior year’s third quarter revenue of $20.8 million. ...

Core Viewpoint - Vaso Corporation reported a slight decline in revenue for Q2 2025, primarily due to lower performance in the professional sales service segment, while maintaining a strong balance sheet with significant deferred revenue growth [2][3][6]. Financial Performance - Revenue for Q2 2025 was $20.0 million, a decrease of 1.3% from $20.2 million in Q2 2024, mainly driven by a 4.0% decline in the professional sales service segment [3][4]. - Gross profit for the quarter was $11.8 million, down by $354 thousand or 2.9% year-over-year [4]. - The company reported a net loss of $197 thousand for Q2 2025, compared to a net income of $1.2 million in the same quarter of 2024 [6][7]. Segment Performance - Revenue in the professional sales service segment decreased by $366 thousand, while the IT segment saw a slight increase of $93 thousand, and the equipment segment rose by $4 thousand [3]. - Selling, general and administrative (SG&A) expenses increased by $1.2 million or 11% to $12.1 million, primarily due to higher personnel costs [5]. Cash Flow and Balance Sheet - Operating cash flow for the three months ended June 30, 2025, was $6.8 million, contributing to a strong cash position of $32.6 million at the end of the reporting period [2][8]. - Total current assets were $49.972 million, and total stockholders' equity was $26.501 million as of June 30, 2025 [15]. Outlook - The company remains cautiously optimistic about the full year 2025, historically achieving better profitability in the later quarters [2].

Core Viewpoint - Vaso Corporation reported record first quarter revenue of $19.5 million for the three months ended March 31, 2025, marking a 3.9% increase year-over-year, with improvements in gross profit and a narrowed net loss [2][3][6]. Financial Performance - Revenue for the first quarter of 2025 was $19.5 million, up from $18.7 million in the same period of 2024, driven by increases in the IT and professional sales service segments [3]. - Gross profit increased by $440 thousand, or 4.0%, to $11.4 million compared to $10.9 million in the first quarter of 2024, attributed to higher revenues [4]. - Selling, general and administrative (SG&A) expenses rose by $332 thousand, or 2.8%, to $12.4 million, mainly due to higher personnel costs in IT and professional sales services [5]. - Operating loss for the first quarter was $1.2 million, an improvement from a loss of $1.5 million in the same quarter of 2024 [6]. - Net loss narrowed to $1.1 million from $1.2 million year-over-year [6]. - Adjusted EBITDA was negative $1.1 million, an improvement from negative $1.3 million in the first quarter of 2024 [7]. Balance Sheet and Cash Flow - As of March 31, 2025, the company had $25.3 million in cash and cash equivalents, with total deferred revenue growing to $35.4 million, a 12.7% increase from the previous year [2][8]. - Net cash used in operating activities improved to $566 thousand from $1.1 million in the first quarter of 2024 [8]. - Total current assets were $45.981 million, while total assets were $77.914 million as of March 31, 2025 [15].